



Contacts: Meg McGilley
Chief Financial Officer
(858) 509-3670

Rob Whetstone
PondelWilkinson, Inc.
(310) 279-5963

Somaxon Pharmaceuticals to Present at the Pacific Growth Equities 2006 Life Sciences Growth Conference

SAN DIEGO, CA – June 9, 2006 – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that Ken Cohen, president and chief executive officer, will present a company update at the Pacific Growth Equities 2006 Life Sciences Growth Conference at the InterContinental Mark Hopkins Hotel, San Francisco, on Wednesday, June 14, 2006, at 1:30 p.m. Pacific Time.

A live webcast of the presentation will be available in the Investor Relations section of the company's website under Event Scheduler at www.somaxon.com. The webcast will be archived and accessible for at least 14 days.

About Somaxon Pharmaceuticals

Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. Somaxon's lead product candidate, SILENOR™ (doxepin hydrochloride), is in Phase 3 clinical trials for the treatment of insomnia. Nalmefene HCl is in a Phase 2/3 clinical trial for pathological gambling and in a pilot Phase 2 trial for smoking cessation. Acamprosate Ca, a potential treatment for movement disorders, is currently in formulation development. For more information, please visit the company's web site at www.somaxon.com.

Somaxon cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Somaxon that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Somaxon's business, including, without limitation: the progress and timing of clinical trials, including for SILENOR and Somaxon's other product candidates; unexpected adverse side effects or inadequate therapeutic efficacy of SILENOR

or Somaxon's other product candidates that could delay or prevent regulatory approval or product development; and other risks detailed in Somaxon's prior press releases as well as in public periodic filings with the Securities and Exchange Commission.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Somaxon undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.

This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

###